AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Twist Bioscience Corporation Common Stock
XNAS · usd
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG006KDCHK2
139.92▲ 4.45 (3.28%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
—
Trading Information
Previous Close
135.47
Day's Range
131.23 – 140.74
52-Week Range
23.30 – 219.71
Volume
1.9M
Avg Volume
2.8M
Share Statistics
Shares Outstanding
Employees
979
Exchange
XNAS
Listed
2018-10-31
Share count as of July 29, 2026

Twist Bioscience Corporation Common Stock (TWST) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Twist Bioscience Corporation Common Stock (TWST)
What is Twist Bioscience Corporation Common Stock's Market Cap?
Twist Bioscience Corporation Common Stock's Market Cap is $8.8B, based on as-reported figures from SEC (XBRL) filings.
What is Twist Bioscience Corporation Common Stock's Price / Sales?
Twist Bioscience Corporation Common Stock's Price / Sales is 20.3×, based on as-reported figures from SEC (XBRL) filings.
What is Twist Bioscience Corporation Common Stock's Revenue (TTM)?
Twist Bioscience Corporation Common Stock's Revenue (TTM) is $431.8M, based on as-reported figures from SEC (XBRL) filings.
What is Twist Bioscience Corporation Common Stock's Net Income (TTM)?
Twist Bioscience Corporation Common Stock's Net Income (TTM) is -$136.7M, based on as-reported figures from SEC (XBRL) filings.
What is Twist Bioscience Corporation Common Stock's EBITDA?
Twist Bioscience Corporation Common Stock's EBITDA is -$119.6M, based on as-reported figures from SEC (XBRL) filings.
What is Twist Bioscience Corporation Common Stock's Diluted EPS (TTM)?
Twist Bioscience Corporation Common Stock's Diluted EPS (TTM) is -2.18, based on as-reported figures from SEC (XBRL) filings.
What is Twist Bioscience Corporation Common Stock's EBITDA Margin?
Twist Bioscience Corporation Common Stock's EBITDA Margin is -27.7%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · TWSTAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenues
YoY growth+23.2%+19.3%+16.9%+16.9%
Costs and expenses:
Cost of revenues
Research and development expenses
Selling, general and administrative expenses
Litigation settlement costs, net of recoveries——
Total costs and expenses
% of revenue130.6%141.4%131.7%130.2%
Loss from operations
% of revenue-30.6%-41.4%-31.7%-30.2%
Gain on sale of business——
Interest income
Other income (expense), net
Income (loss) before income taxes
Income tax expense
Net (loss) income
% of revenue-29.6%-39.8%-29.4%-27.4%
Other comprehensive (loss) income:
Change in unrealized gain (loss) on investments
Foreign currency translation adjustment
Comprehensive (loss) income
Net (loss) income per share — basic (in usd per share)
Net (loss) income per share — diluted (in usd per share)